Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation.

Ahmed I, Gertner E, Nelson WB, House CM, Dahiya R, Anderson CP, Benditt DG, Zhu DW.

Heart Rhythm. 2010 Jun;7(6):745-9. doi: 10.1016/j.hrthm.2010.02.018. Epub 2010 Feb 20.

PMID:
20176137
2.

Pacemaker or defibrillator surgery without interruption of anticoagulation.

Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, Simpson CS, Ayala-Paredes F, Coutu B, Leiria TL, Essebag V; BRUISE CONTROL Investigators..

N Engl J Med. 2013 May 30;368(22):2084-93. doi: 10.1056/NEJMoa1302946. Epub 2013 May 9.

3.

Cardiac resynchronization therapy device implantation in patients with therapeutic international normalized ratios.

Ghanbari H, Feldman D, Schmidt M, Ottino J, Machado C, Akoum N, Wall TS, Daccarett M.

Pacing Clin Electrophysiol. 2010 Apr;33(4):400-6. doi: 10.1111/j.1540-8159.2010.02703.x. Epub 2010 Feb 18.

PMID:
20180915
4.

Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: wide variability of perioperative bridging in Canada.

Krahn AD, Healey JS, Simpson CS, Essebag V, Sivakumaran S, Birnie DH.

Heart Rhythm. 2009 Sep;6(9):1276-9. doi: 10.1016/j.hrthm.2009.05.027. Epub 2009 Jun 6.

PMID:
19716082
5.

Reduced-dose warfarin or interrupted warfarin with heparin bridging for pacemaker or defibrillator implantation: a randomized trial.

Schulman S, Healey JS, Douketis JD, Delaney J, Morillo CA.

Thromb Res. 2014 Oct;134(4):814-8. doi: 10.1016/j.thromres.2014.07.028. Epub 2014 Aug 1.

PMID:
25127655
6.

Implantation of cardiac rhythm devices without interruption of oral anticoagulation compared with perioperative bridging with low-molecular weight heparin.

Tischenko A, Gula LJ, Yee R, Klein GJ, Skanes AC, Krahn AD.

Am Heart J. 2009 Aug;158(2):252-6. doi: 10.1016/j.ahj.2009.06.005.

PMID:
19619702
7.

Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol.

Jaffer AK, Ahmed M, Brotman DJ, Bragg L, Seshadri N, Qadeer MA, Klein A.

J Thromb Thrombolysis. 2005 Aug;20(1):11-6.

PMID:
16133889
8.

Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices.

Cano O, Muñoz B, Tejada D, Osca J, Sancho-Tello MJ, Olagüe J, Castro JE, Salvador A.

Heart Rhythm. 2012 Mar;9(3):361-7. doi: 10.1016/j.hrthm.2011.10.010. Epub 2011 Oct 12.

PMID:
22001709
9.

Risk of pocket hematoma in patients on chronic anticoagulation with warfarin undergoing electrophysiological device implantation: a comparison of different peri-operative management strategies.

Proietti R, Porto I, Levi M, Leo A, Russo V, Kalfon E, Biondi-Zoccai G, Roux JF, Birnie DH, Essebag V.

Eur Rev Med Pharmacol Sci. 2015 Apr;19(8):1461-79. Review.

10.

Meta-analysis of safety and efficacy of uninterrupted warfarin compared to heparin-based bridging therapy during implantation of cardiac rhythm devices.

Ghanbari H, Phard WS, Al-Ameri H, Latchamsetty R, Jongnarngsin K, Crawford T, Good E, Chugh A, Oral H, Bogun F, Morady F, Pelosi F Jr.

Am J Cardiol. 2012 Nov 15;110(10):1482-8. doi: 10.1016/j.amjcard.2012.06.057. Epub 2012 Aug 17. Review.

PMID:
22906894
11.

No increased bleeding events with continuation of oral anticoagulation therapy for patients undergoing cardiac device procedure.

Li HK, Chen FC, Rea RF, Asirvatham SJ, Powell BD, Friedman PA, Shen WK, Brady PA, Bradley DJ, Lee HC, Hodge DO, Slusser JP, Hayes DL, Cha YM.

Pacing Clin Electrophysiol. 2011 Jul;34(7):868-74. doi: 10.1111/j.1540-8159.2011.03049.x. Epub 2011 Mar 16.

PMID:
21410724
12.

Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation.

Wysokinski WE, McBane RD, Daniels PR, Litin SC, Hodge DO, Dowling NF, Heit JA.

Mayo Clin Proc. 2008 Jun;83(6):639-45. doi: 10.4065/83.6.639. Erratum in: Mayo Clin Proc. 2008 Jul;83(7):851.

PMID:
18533080
13.

Cardiac rhythm device surgery with uninterrupted oral anticoagulation.

Tyagi G, Pai SM, Pai RG.

Future Cardiol. 2013 Nov;9(6):763-6. doi: 10.2217/fca.13.80.

PMID:
24180532
14.

Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide.

Jamula E, Douketis JD, Schulman S.

J Thromb Haemost. 2008 Oct;6(10):1615-21. doi: 10.1111/j.1538-7836.2008.03080.x. Epub 2008 Jul 12. Review.

15.

Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation.

Tompkins C, Cheng A, Dalal D, Brinker JA, Leng CT, Marine JE, Nazarian S, Spragg DD, Sinha S, Halperin H, Tomaselli GF, Berger RD, Calkins H, Henrikson CA.

J Am Coll Cardiol. 2010 May 25;55(21):2376-82. doi: 10.1016/j.jacc.2009.12.056.

16.

Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims.

Hess PL, Greiner MA, Fonarow GC, Klaskala W, Mills RM, Setoguchi S, Al-Khatib SM, Hernandez AF, Curtis LH.

Clin Cardiol. 2012 Nov;35(11):649-57. doi: 10.1002/clc.22064. Epub 2012 Oct 15.

17.

Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.

Bui HT, Krisnaswami A, Le CU, Chan J, Shenoy BN.

Am J Cardiol. 2009 Nov 15;104(10):1429-33. doi: 10.1016/j.amjcard.2009.06.065. Epub 2009 Sep 26.

PMID:
19892063
18.

A randomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation.

Michaud GF, Pelosi F Jr, Noble MD, Knight BP, Morady F, Strickberger SA.

J Am Coll Cardiol. 2000 Jun;35(7):1915-8.

19.
20.

Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial.

Essebag V, Healey JS, Ayala-Paredes F, Kalfon E, Coutu B, Nery P, Verma A, Sapp J, Philippon F, Sandhu RK, Coyle D, Eikelboom J, Wells G, Birnie DH.

Am Heart J. 2016 Mar;173:102-7. doi: 10.1016/j.ahj.2015.12.007. Epub 2015 Dec 19.

PMID:
26920602

Supplemental Content

Support Center